“we should in the next couple of months get additional PKPD data from that molecule, which will be our potential opportunity to go to three-monthly.”

In context

“of metabolic studies that we'd expect to do, or would you pursue any maybe inflammation or neuropsych indications or would you pursue GLP-1 active comparator studies? I'm trying to think of how you could separate yourself in a broad phase three program. Thank you. Albert Bourla: Yeah. Thank you. Thank you, Jeff. So, Chris, monthly, or more and then additional studies? Chris Boshoff: So thank you for the question. So 3944 is, as we demonstrated, the first peptide that can be administered monthly. And potentially, yes, we can go longer, but for 3944, our aim is as a monthly maintenance therapy. As I mentioned, we do have another molecule, a peptide currently in phase one, which has a prodrug, a propeptide with a potential for three-monthly administration. That's currently in phase one, and we should in the next couple of months get additional PKPD data from that molecule, which will be our potential opportunity to go to three-monthly. The second question, the initial phase three programs were before based before five and six based before is the one in patients without type two diabetes. That's currently ongoing with weekly testing, including the high dose of 2.4 milligrams weekly. Vespa five in patients with type two diabetes, and VESPA six, the study that will include monthly dosing. Beyond that, we plan to start seven studies. We haven't shown or revealed what these studies are gonna be, but you're absolutely correct that beyond cardiovascular metabolic, we are looking at other opportunities to differentiate and also to differentiate with our combinations. For instance, with Amelin or with the GIPA currently in phase one. Albert Bourla: Thank you. Next question, please. Operator: Thank you. Our next question comes fr”